Abstract
Japanese rheumatologists consider bucillamine (Buc) to be a useful disease-modifying antirheumatic drug (DMARD) and often give Buc to patients with rheumatoid arthritis (RA) prior to administering methotrexate (MTX). However, no large studies on the efficacy and safety of Buc in RA patients have been published in English to date. We therefore investigated the clinical course of RA patients treated with Buc and compared the results with those for patients treated with MTX to evaluate and confirm the place of Buc in therapeutic strategies for RA in Japan. Our results suggested that Buc should be given to patients with moderately active RA either before or after the administration of MTX because its efficacy can be judged within 3 months and because serious adverse events are rare. Issues like the ability of Buc to prevent joint destruction and its efficacy and safety when combined with agents like etanercept require future study.
| Original language | English |
|---|---|
| Pages (from-to) | 85-91 |
| Number of pages | 7 |
| Journal | Modern Rheumatology |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2006 Apr |
| Externally published | Yes |
Fingerprint
Keywords
- Bucillamine (BUC)
- Disease activity score (DAS)
- Disease-modifying antirheumatic drug (DMARD)
- Methotrexate(MTX)
- Rheumatoid arthritis (RA)
ASJC Scopus subject areas
- Rheumatology
- Immunology
Cite this
Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. / Sekiguchi, Naoya; Kameda, Hideto; Amano, Koichi; Takeuchi, Tsutomu.
In: Modern Rheumatology, Vol. 16, No. 2, 04.2006, p. 85-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis
AU - Sekiguchi, Naoya
AU - Kameda, Hideto
AU - Amano, Koichi
AU - Takeuchi, Tsutomu
PY - 2006/4
Y1 - 2006/4
N2 - Japanese rheumatologists consider bucillamine (Buc) to be a useful disease-modifying antirheumatic drug (DMARD) and often give Buc to patients with rheumatoid arthritis (RA) prior to administering methotrexate (MTX). However, no large studies on the efficacy and safety of Buc in RA patients have been published in English to date. We therefore investigated the clinical course of RA patients treated with Buc and compared the results with those for patients treated with MTX to evaluate and confirm the place of Buc in therapeutic strategies for RA in Japan. Our results suggested that Buc should be given to patients with moderately active RA either before or after the administration of MTX because its efficacy can be judged within 3 months and because serious adverse events are rare. Issues like the ability of Buc to prevent joint destruction and its efficacy and safety when combined with agents like etanercept require future study.
AB - Japanese rheumatologists consider bucillamine (Buc) to be a useful disease-modifying antirheumatic drug (DMARD) and often give Buc to patients with rheumatoid arthritis (RA) prior to administering methotrexate (MTX). However, no large studies on the efficacy and safety of Buc in RA patients have been published in English to date. We therefore investigated the clinical course of RA patients treated with Buc and compared the results with those for patients treated with MTX to evaluate and confirm the place of Buc in therapeutic strategies for RA in Japan. Our results suggested that Buc should be given to patients with moderately active RA either before or after the administration of MTX because its efficacy can be judged within 3 months and because serious adverse events are rare. Issues like the ability of Buc to prevent joint destruction and its efficacy and safety when combined with agents like etanercept require future study.
KW - Bucillamine (BUC)
KW - Disease activity score (DAS)
KW - Disease-modifying antirheumatic drug (DMARD)
KW - Methotrexate(MTX)
KW - Rheumatoid arthritis (RA)
UR - http://www.scopus.com/inward/record.url?scp=33645999341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645999341&partnerID=8YFLogxK
U2 - 10.1007/s10165-005-0466-y
DO - 10.1007/s10165-005-0466-y
M3 - Article
C2 - 16633927
AN - SCOPUS:33645999341
VL - 16
SP - 85
EP - 91
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 2
ER -